**7. Future prospects**

Exponential advancement in DNA methylation-based biomarker growth has been observed over the last decade. A variety of cfDNA and tissue-dependent screening assays have paved their way into clinics due to the consistency of DNA and methylation patterns. Several tests for early detection of colon, lung, and prostate cancer are commercial success based on DNA methylation biomarkers. New technologies that enable the rapid identification of methylation signatures directly from the blood can promote sample-to-respond solutions, allowing molecular diagnostics for the next-generation point of care. Besides, ongoing work on liquid biopsies together with the latest advanced technologies such as digital PCR, bisulfite sequencing, methyl immune precipitation coupled with next-generation sequencing, and methylation arrays together with advanced statistical data analysis will mitigate the complicated problems of non-invasive system creation by overcoming the existing challenges to precision medicine.
